Medivir to present at the ProHearings shared Capital Markets Day
Medivir AB announced its upcoming presentation at the ProHearings Shared Capital Markets Day on October 14, 2021. The event will be accessible via Medivir's website, ensuring stakeholders can stay informed. Medivir focuses on developing innovative drugs for cancer treatment, highlighting MIV-818, a pro-drug aimed at selectively targeting liver cancer cells to reduce side effects. The company also maintains strategic collaborations, such as its partnership with IGM Biosciences for Birinapant, a treatment for solid tumors. Medivir's shares are listed under the ticker MVIR on Nasdaq Stockholm.
- None.
- None.
STOCKHOLM, Oct. 11, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the ProHearings shared Capital Markets Day, October 14, 2021.
The presentation will be available through Medivir´s website; www.medivir.com.
More information about the event is available at the organizer's website: www.prohearings.com.
For additional information, please contact
Magnus Christensen, interim CEO and CFO
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/medivir-to-present-at-the-prohearings-shared-capital-markets-day-301396808.html
SOURCE Medivir
FAQ
When will Medivir present at the Capital Markets Day?
How can I access Medivir's presentation?
What is Medivir focused on developing?
What is MIV-818?
What collaborations does Medivir have?
Where are Medivir's shares listed?
